[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"localized-breast-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:localized-breast-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100414753","phase-2-per-operative-radiotherapy-by-papillon-tm-in-localized-breast-cancer-100414753",false,"NCT04680715","Per-Operative Radiotherapy by Papillon +TM in Localized Breast Cancer","Per-Operative Radiotherapy (RPO) by Papillon +TM in Localized Breast Cancer : Faisability and Toxicity Study","RPOS+2","Inclusion Criteria:\n\n* Patient with invasive ductal adenocarcinoma \\\u003C=2cm, evaluate on all radiological exams;\n* Women aged 65 years or older (patients 65 years of age in the year may be included);\n* Grade 1 or 2 unifocal adenocarcinoma, all index KI67, positive HR, negative HER2 status;\n* T0 or T1, N0 radio-clinic;\n* Operable patient with breast volume compatible with conservative surgery;\n* Patient with prior malignancy or other concurrent malignancies are eligible, including bilateral breast cancer\n* Patients who have been made aware of the information sheet and have given their written signed informed consent;\n* Patients benefitting from social health insurance coverage\n\nExclusion Criteria:\n\n* Age less than 65 years (except if 65 years obtained during the year)\n* Patient with an exclusive in situ carcinoma\n* Patient with lymphatic invasion \u002F peri-nerve involvement \u002F vascular emboli\n* Patient with a lobular adenocarcinoma\n* Patient with metastatic disease\n* Multifocal tumor\n* Patient with grade 3 or N+ disease\n* N1 proved by ultrasound guided\n* patient unable to express her consent\n* Patient deprived placed under the authority of a tutor\n* Female patients who are pregnant or breastfeeding\n* Vulnerable patient: as defined in article L1121-5 à -8","FEMALE","65 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Phase II study; open recruitment, multicentrique. The aim of this clinical research is to evaluate faisability and toxicity of the per-operative radiotherapy using PAPILLON + TM device for localized breast cancers patients over 65 years.",[27],"Localized Breast Cancer","RECRUITING","2026-01-28",{"date":31,"type":32},"2026-01-29","ACTUAL",{"date":34,"type":32},"2021-07-16",{"date":36,"type":21},"2028-06",{"name":38,"class":39},"Centre Antoine Lacassagne","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":17,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":50,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100605687","mon-parcours-de-vie-localized-breast-cancer-announcement-support-information-on-the-disease-and-treatments-pilot-study-to-assess-the-value-of-written-information-documents-100605687","NCT07165756","\"Mon Parcours de Vie\" Localized Breast Cancer: Announcement, Support, Information on the Disease and Treatments. Pilot Study to Assess the Value of Written Information Documents.","MaVie","Inclusion Criteria:\n\n* Patient with localized breast cancer consulting for medical treatment (chemotherapy+\u002F- immunotherapy+\u002Fanti-HER2 targeted therapy)\n* Diagnosis of invasive breast cancer for which there is an indication for local and medical treatment.\n* WHO ≤ 1\n* Patient has understood, signed and dated the consent form\n* Patient affiliated to the social security system\n\nExclusion Criteria:\n\n* Patient with metastatic breast cancer\n* History of other cancer\n* Patient unable to read or speak French\n* Persons deprived of liberty or under guardianship (including curatorship).","18 Years",{"count":49,"type":21},60,"14 Days","OBSERVATIONAL","Since late 2019, the French association \"MON PARCOURS DE VIE\" has developed books donated by caregivers at cancer centers in France. These documents are available online: https:\u002F\u002Fwww.monparcoursdevie.fr\u002F. They are highly acclaimed by women suffering from the breast cancer, as well as by caregivers. Four volumes have been written: 'Metastatic breast cancer', 'Localized breast cancer', 'Preserving my well-being', 'After breast cancer', and finally 'Breast cancer, support and accompaniment'.\n\nThe aim in writing these information brochures is to provide clear, concise, useful information, with pedagogy, gentleness, benevolence, humility, cheerfulness, imagination, simplicity and an innovative presentation. These documents are a new and innovative method of providing information, delivered by caregivers who work with women suffering from breast cancer. It extends the human support so necessary in this disease.\n\nIt seemed important to us to evaluate, through a clinical study, the impact of the written documents \"Mon Parcours de Vie\" - volume 2: Breast cancer and volume 3: Preserving my well-being, concerning the announcement of a localized breast cancer in the initial management for the first time in the breast pathway. The objectives of the clinical study are to evaluate the acceptability and impact of these two written information documents on anxiety generated by the announcement of cancer and treatment.",[27],[55,56,57],"Announcement of cancer and treatment","Breast cancer","Information documents","2025-12-19",{"date":60,"type":32},"2025-12-22",{"date":62,"type":32},"2025-09-09",{"date":64,"type":21},"2026-11-01",{"name":66,"class":39},"Institut de Cancérologie de Lorraine",1]